<table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="tbl5" position="float"><object-id pub-id-type="doi">10.7554/eLife.15691.017</object-id><label>Table 5.</label><caption><p>Adverse events of patients receiving TILA-TACE or cTACE.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.15691.017">http://dx.doi.org/10.7554/eLife.15691.017</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top">Adverse events*</th><th valign="top">TILA-TACE</th><th valign="top">cTACE<sup>&#8224;</sup></th></tr></thead><tbody><tr><td valign="top"><bold>Pain</bold></td><td valign="top">5 out of 30</td><td valign="top">3 out of 27</td></tr><tr><td valign="top"><bold>Fever (&#8805;38.5)<sup>&#8225;</sup></bold></td><td valign="top">13 out of 30</td><td valign="top">9 out of 27</td></tr></tbody></table><table-wrap-foot><fn id="tblfn20"><p>* The adverse events monitored also include acute hepatic decomposition, irreversible hepatic decompensation, respiratory failure or decompensation, biliary stricture or obstruction, liver abscess, gastrointestinal bleeding, arterial thrombosis, arterial-portal shunting. These events were not observed in the patients.</p></fn><fn id="tblfn21"><p><sup>&#8224;</sup> Patients were retrospectively retrieved from our database.</p></fn><fn id="tblfn22"><p><sup>&#8225;</sup> Mild fever occurred to all patients.</p></fn></table-wrap-foot></table-wrap>